AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19379093 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics
Number of subjects: 0
Study 19379093 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (an antipsychotic)
Number of subjects: 0
Study 16817288 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin and mannitol added to the pump prime (Group A)
Number of subjects: 36
Study 16817288 — intervention group
Group type: COMPARATOR
Intervention: Heparin-coated perfusion system (Group B)
Number of subjects: 36
Study 16817288 — intervention group
Group type: COMPARATOR
Intervention: Leukocyte-depletion arterial line filter (Group C)
Number of subjects: 36
Study 16817288 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group D)
Number of subjects: 36
Study 12771320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary plant sterol ester (PSE) at a dosage of 2.8 g/d (1.68 g/d phytosterols) for 4 weeks
Number of subjects: 60
Study 12771320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary plant sterol ester (PSE) for II, IV, and VV phenotypes
Number of subjects: 60
Study 12771320 — intervention group
Group type: COMPARATOR
Intervention: Control group (margarine without PSE)
Number of subjects: 60
Study 12771320 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP concentration
Number of subjects: 60
Study 10857945 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (0.5, 1.0, 2.0 mg in study 1 and 4.0 mg in study 2)
Number of subjects: 16
Study 10857945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9118656 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (1.5 g of amino acids/kg/day with 45% branch-chain amino acids)
Number of subjects: 69
Study 9118656 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (1.1 g/kg/day of amino acids with 45% branch-chain amino acids)
Number of subjects: 69
Study 9118656 — intervention group
Group type: COMPARATOR
Intervention: Group A (1.5 g of amino acids/kg/day with 23% branch-chain amino acids)
Number of subjects: 69
Study 8175200 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraflo II
Number of subjects: 30
Study 8175200 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 29551231 — intervention group
Group type: EXPERIMENTAL
Intervention: Once per week (QW) SBRT, 40 Gy in 5 fractions
Number of subjects: 152
Study 29551231 — intervention group
Group type: COMPARATOR
Intervention: Every other day (EOD) SBRT, 40 Gy in 5 fractions
Number of subjects: 152
Study 26718095 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician manager-centered hypertension management intervention
Number of subjects: 102
Study 26718095 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 102
Study 24809759 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma APGAR system
Number of subjects: 468
Study 24809759 — intervention group
Group type: COMPARATOR
Intervention: ACT™/CACT™
Number of subjects: 468
Study 24809759 — intervention group
Group type: EXPERIMENTAL
Intervention: Controller medications
Number of subjects: 468
Study 22289123 — intervention group
Group type: EXPERIMENTAL
Intervention: New road tunnel intervention
Number of subjects: 4
Study 22289123 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive samplers for NO(2)
Number of subjects: 4
Study 22289123 — intervention group
Group type: EXPERIMENTAL
Intervention: Land use regression model (LUR)
Number of subjects: 4
Study 20099203 — intervention group
Group type: EXPERIMENTAL
Intervention: EFTT with imaginal confrontation (IC)
Number of subjects: 45
Study 20099203 — intervention group
Group type: EXPERIMENTAL
Intervention: EFTT with empathic exploration (EE)
Number of subjects: 45
Study 18598735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (100-200 mg/day)
Number of subjects: 42
Study 18598735 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (40-80 mg/day)
Number of subjects: 42
Study 15796627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 15796627 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT)
Number of subjects: 0
Study 12091330 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell transplantation (PBSCT)
Number of subjects: 126
Study 12091330 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 126
Study 12091330 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSCT
Number of subjects: 126
Study 12091330 — intervention group
Group type: COMPARATOR
Intervention: BMT
Number of subjects: 126
Study 10320602 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25% (1.0 ml x kg(‐1))
Number of subjects: 80
Study 10320602 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% (1.0 ml x kg(‐1))
Number of subjects: 80
Study 7853584 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cycles of 100 mg/m2 neoadjuvant cisplatin before radical cystectomy (arm B)
Number of subjects: 122
Study 7853584 — intervention group
Group type: COMPARATOR
Intervention: Control group treated only with radical cystectomy (arm A)
Number of subjects: 122
Study 1826253 — intervention group
Group type: EXPERIMENTAL
Intervention: prazosin (alpha 1-adrenergic blocker)
Number of subjects: 26
Study 1826253 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol (cardioselective beta-adrenergic blocker)
Number of subjects: 26
Study 1826253 — intervention group
Group type: EXPERIMENTAL
Intervention: carteolol (nonselective beta-adrenergic blocker)
Number of subjects: 26
Study 7036354 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 25
Study 7036354 — intervention group
Group type: COMPARATOR
Intervention: Nafcillin or Methicillin
Number of subjects: 25
Study 7036354 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (IV therapy)
Number of subjects: 25
Study 7036354 — intervention group
Group type: COMPARATOR
Intervention: Nafcillin/Methicillin (IV therapy)
Number of subjects: 25
Study 7036354 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (oral therapy)
Number of subjects: 25
Study 30794658 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg)
Number of subjects: 40
Study 30794658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30794658 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice a day for 7 days)
Number of subjects: 40
Study 30794658 — intervention group
Group type: COMPARATOR
Intervention: Placebo (200 mg twice a day for 7 days)
Number of subjects: 40
Study 29793488 — intervention group
Group type: COMPARATOR
Intervention: Normolip 5 (N)
Number of subjects: 20
Study 29793488 — intervention group
Group type: EXPERIMENTAL
Intervention: Argicolina (A)
Number of subjects: 20
Study 26739737 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of physiological saline by an intrauterine catheter
Number of subjects: 192
Study 26739737 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of saline intravaginally
Number of subjects: 192
Study 24503560 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (80 kV, 600 mAs, 50% reduction in contrast medium dose)
Number of subjects: 84
Study 24503560 — intervention group
Group type: COMPARATOR
Intervention: Group A (120 kV, 400 mAs)
Number of subjects: 84
Study 22147447 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (50 mg/m² weekly), 5-fluorouracil (250 mg/m² for 5 days/week), pelvic radiation (45 Gy/1.8 Gy/fraction for 5 days/week)
Number of subjects: 36
Study 19021619 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical alkalinized lidocaine (PSD597) 200 mg lidocaine, alkalinized with 8.4% sodium bicarbonate solution, for 5 consecutive days
Number of subjects: 102
Study 19021619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 17999405 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session family intervention
Number of subjects: 235
Study 17999405 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 235
Study 15121020 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg ibandronate
Number of subjects: 520
Study 15121020 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ibandronate
Number of subjects: 520
Study 15121020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 11777712 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop-and-chop technique
Number of subjects: 30
Study 11777712 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaco-out technique
Number of subjects: 30
Study 11777712 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 30
Study 9844703 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with 150 micrograms clonidine in 15 ml bupivacaine 0.25% solution with 37.5 micrograms epinephrine (group C + E)
Number of subjects: 44
Study 9844703 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia with 150 micrograms clonidine in 15 ml bupivacaine 0.25% solution without epinephrine (group C)
Number of subjects: 44
Study 8088613 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with autologous bone marrow support (ABMS)
Number of subjects: 200
Study 8088613 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy regimens with ABMS (cyclophosphamide, cisplatin, thiotepa or cyclophosphamide, carboplatin, mitoxantrone)
Number of subjects: 200
Study 8088613 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose salvage chemotherapy
Number of subjects: 200
Study 2684006 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline (1 g)
Number of subjects: 87
Study 2684006 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone (400 mg)
Number of subjects: 87
Study 2684006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 4317858 — intervention group
Group type: EXPERIMENTAL
Intervention: 780 SE (300 mg)
Number of subjects: 0
Study 4317858 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (40 mg)
Number of subjects: 0
Study 31806947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Geriatric Team (MGT)
Number of subjects: 62
Study 31806947 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 29247112 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative SpO2 target of 88%-92%
Number of subjects: 120
Study 29247112 — intervention group
Group type: COMPARATOR
Intervention: Liberal SpO2 target of >94%
Number of subjects: 120
Study 25567555 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (up to 3 mg)
Number of subjects: 25
Study 25567555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 24317185 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking for 20 min at aerobic levels
Number of subjects: 20
Study 24317185 — intervention group
Group type: COMPARATOR
Intervention: Attentional control group watching a video
Number of subjects: 20
Study 21947207 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanols (8.8 g/day for 10 weeks, followed by 4.5 g at breakfast)
Number of subjects: 38
Study 21947207 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanols (4.5 g at breakfast)
Number of subjects: 38
Study 21947207 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanols (8.8 g/day for 10 weeks)
Number of subjects: 38
Study 21947207 — intervention group
Group type: COMPARATOR
Intervention: Control group (no plant stanols)
Number of subjects: 38
Study 18840641 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronate 150 mg/month (n = 47)
Number of subjects: 93
Study 18840641 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 46)
Number of subjects: 93
Study 17727401 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral index monitoring
Number of subjects: 50
Study 17727401 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bispectral index monitoring)
Number of subjects: 50
Study 16216961 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 29
Study 16216961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 12114358 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 44
Study 12114358 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 44
Study 10222636 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational-nursing intervention using the Progressively Lowered Stress Threshold (PLST) model
Number of subjects: 0
Study 10222636 — intervention group
Group type: COMPARATOR
Intervention: Routine information and referrals for case management, community-based services, and support groups
Number of subjects: 0
Study 7838507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 100
Study 7838507 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 100
Study 2365760 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice booklet and support visits
Number of subjects: 3
Study 2365760 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet only
Number of subjects: 3
Study 2365760 — intervention group
Group type: EXPERIMENTAL
Intervention: No intervention
Number of subjects: 3
Study 2365760 — intervention group
Group type: COMPARATOR
Intervention: Non-night waking infants (comparison group)
Number of subjects: 3
Study 221871 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose conjugated estrogens with cyclic progesterone
Number of subjects: 168
Study 221871 — intervention group
Group type: COMPARATOR
Intervention: Placebos
Number of subjects: 168
Study 31521520 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 44
Study 31521520 — intervention group
Group type: COMPARATOR
Intervention: PDRN injection
Number of subjects: 44
Study 31484712 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine (titrated to produce mild or moderate serum urate elevation)
Number of subjects: 75
Study 31484712 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine (mild or moderate dosing)
Number of subjects: 75
Study 31484712 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine (higher dosing)
Number of subjects: 75
Study 31484712 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine
Number of subjects: 75
Study 31484712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 27955995 — intervention group
Group type: EXPERIMENTAL
Intervention: AADvac1
Number of subjects: 30
Study 27955995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26549785 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 400 μg
Number of subjects: 37
Study 26549785 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrronium bromide 50 μg
Number of subjects: 37
Study 23362890 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 50 µg (Group C)
Number of subjects: 90
Study 23362890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 5 µg (Group D)
Number of subjects: 90
Study 23362890 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 0.5% 3 ml + saline 0.5 ml (Group B)
Number of subjects: 90
Study 20933337 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 77
Study 20933337 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 77
Study 19528362 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented volume removal therapy
Number of subjects: 145
Study 19528362 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational cohort of 37 patients
Number of subjects: 145
Study 16732778 — intervention group
Group type: EXPERIMENTAL
Intervention: Live music therapy
Number of subjects: 31
Study 16732778 — intervention group
Group type: COMPARATOR
Intervention: Recorded music therapy
Number of subjects: 31
Study 16732778 — intervention group
Group type: COMPARATOR
Intervention: No music therapy
Number of subjects: 31
Study 14617526 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion
Number of subjects: 10
Study 14617526 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 10
Study 10066844 — intervention group
Group type: EXPERIMENTAL
Intervention: Licostinel (0.03 to 3.0 mg/kg)
Number of subjects: 64
Study 10066844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 7726818 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reinforcement
Number of subjects: 6
Study 7726818 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effects of methylphenidate and self-reinforcement
Number of subjects: 6
Study 7726818 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg)
Number of subjects: 6
Study 7726818 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.7 mg/kg)
Number of subjects: 6
Study 7726818 — intervention group
Group type: COMPARATOR
Intervention: Drug placebo
Number of subjects: 6
Study 7726818 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent reinforcers
Number of subjects: 6
Study 2252187 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 50
Study 2252187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6102838 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic receptor blocking therapy
Number of subjects: 183
Study 6102838 — intervention group
Group type: COMPARATOR
Intervention: Control (no beta-blocker therapy)
Number of subjects: 183
Study 30763396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-affective symptoms
Number of subjects: 568
Study 27933720 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone grafting
Number of subjects: 51
Study 27933720 — intervention group
Group type: COMPARATOR
Intervention: Non-grafting (control)
Number of subjects: 51
Study 27933720 — intervention group
Group type: COMPARATOR
Intervention: Both groups (test and control)
Number of subjects: 51
Study 24314348 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin administration
Number of subjects: 22
Study 24314348 — intervention group
Group type: COMPARATOR
Intervention: Saline administration
Number of subjects: 22
Study 24314348 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (placebo)
Number of subjects: 22
Study 24314348 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin and Saline (both groups)
Number of subjects: 22
Study 23155432 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insertion (day 5-9 after mifepristone)
Number of subjects: 129
Study 23155432 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion (at 3-4 weeks after mifepristone)
Number of subjects: 129
Study 20147617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glycoprotein 2b/3a (GP2b/3a) antagonists
Number of subjects: 81918
Study 20147617 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienopyridines
Number of subjects: 81918
Study 20147617 — intervention group
Group type: COMPARATOR
Intervention: Control group (assumed 3% major bleeding rate)
Number of subjects: 81918
Study 20147617 — intervention group
Group type: COMPARATOR
Intervention: Active-controlled thienopyridine trial
Number of subjects: 81918
Study 17373923 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic venous pressure gradient (HVPG) measurement
Number of subjects: 60
Study 17373923 — intervention group
Group type: COMPARATOR
Intervention: HVPG <or= 22 mmHg
Number of subjects: 60
Study 17373923 — intervention group
Group type: COMPARATOR
Intervention: HVPG > 22 mmHg
Number of subjects: 60
Study 17373923 — intervention group
Group type: EXPERIMENTAL
Intervention: Encephalopathy
Number of subjects: 60
Study 17373923 — intervention group
Group type: EXPERIMENTAL
Intervention: Model for End‐Stage Liver Disease (MELD) score > 25
Number of subjects: 60
Study 15998891 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (600 IU on alternate days)
Number of subjects: 39876
Study 12490017 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous dose of antibiotic (200 mg of ofloxacin) during anesthetic induction
Number of subjects: 81
Study 12490017 — intervention group
Group type: COMPARATOR
Intervention: Treatment doses of antibiotic (400 mg of ofloxacin per day) until the nephrostomy catheter was removed
Number of subjects: 81
Study 12490017 — intervention group
Group type: COMPARATOR
Intervention: Both groups (single-dose vs short-course)
Number of subjects: 81
Study 10023700 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC Quality of Life Questionnaire
Number of subjects: 206
Study 10023700 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC pain subscale
Number of subjects: 206
Study 10023700 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall QOL
Number of subjects: 206
Study 7502282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 98
Study 7502282 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 98
Study 2311806 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 97
Study 2311806 — intervention group
Group type: COMPARATOR
Intervention: Parenteral pethidine
Number of subjects: 97
Study 6256422 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) treatment in vivo
Number of subjects: 0
Study 6256422 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine incubation in vitro
Number of subjects: 0
Study 6256422 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MP and histamine treatments
Number of subjects: 0
Study 6256422 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) in vitro
Number of subjects: 0
Study 6256422 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (1 x 10(‐3) M) addition in vitro with MP
Number of subjects: 0
Study 31817328 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based anxiety prevention program
Number of subjects: 461
Study 31817328 — intervention group
Group type: COMPARATOR
Intervention: School-as-usual control group
Number of subjects: 461
Study 29132988 — intervention group
Group type: EXPERIMENTAL
Intervention: PnuBioVax (50, 200, 500 µg)
Number of subjects: 36
Study 29132988 — intervention group
Group type: EXPERIMENTAL
Intervention: PnuBioVax (200 µg and 500 µg)
Number of subjects: 36
Study 29132988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36